Efficacy of subsequent therapies in patients (pts) with advanced ovarian cancer (AOC) in the phase III PAOLA-1/ENGOT-ov25 trial according to whether disease progression occurred during or after the end of olaparib (ola) maintenance

被引：0

作者：

Harter, Philipp

Mouret-Reynier, Marie-Ange

Lorusso, Domenica

Cropet, Claire

Guerra, Eva M.

Wolfrum-Ristau, Pia

Matsumoto, Takashi

Vergote, Ignace

Colombo, Nicoletta

Maenpaa, Johanna Unelma

Lebreton, Coriolan

de Gregorio, Nikolaus

Mosconi, Anna Maria

Rubio-Perez, Maria Jesus

Bourgeois, Hugues

Fasching, Peter A.

Hardy-Bessard, Anne-Claire

Denschlag, Dominik

Pujade-Lauraine, Eric

Ray-Coquard, Isabelle Laure

机构：

[1] Kliniken Essen Mitte, Essen, Germany

[2] AGO, Essen, Germany

[3] Ctr Jean Perrin, Clermont Ferrand, France

[4] GINECO, Clermont Ferrand, France

[5] Fdn Policlin Univ A Gemelli IRCCS, Ist Tumori Milano, Rome, Italy

[6] Univ Cattolica Sacro Cuore, Rome, Italy

[7] MITO, Rome, Italy

[8] Ctr Leon Berard, Lyon, France

[9] GINECO, Lyon, France

[10] Hosp Univ Ramon & Cajal, Madrid, Spain

[11] GEICO, Madrid, Spain

[12] Paracelsus Med Univ Salzburg, Salzburg, Austria

[13] AGO Au, Salzburg, Austria

[14] Ehime Univ Hosp, Toon, Japan

[15] GOTIC, Toon, Japan

[16] Univ Hosp Leuven, Leuven Canc Inst, Leuven, Belgium

[17] BGOG, Leuven, Belgium

[18] Univ Milano Bicocca, Milan, Italy

[19] European Inst Oncol IRCCS, Milan, Italy

[20] MANGO, Milan, Italy

[21] Tampere Univ Hosp, Tampere, Finland

[22] NSGO, Tampere, Finland

[23] Inst Bergonie, Bordeaux, France

[24] GINECO, Bordeaux, France

[25] Univ Klinikum Ulm, Klin Frauenheilkunde & Geburtshilfe, Ulm, Germany

[26] AGO, Ulm, Germany

[27] SC Oncol Med Osp S Maria della Misericordia AO Pe, Perugia, Italy

[28] MITO, Perugia, Italy

[29] Hosp Reina Sofia, Cordoba, Spain

[30] GEICO, Cordoba, Spain

[31] Ctr Jean Bernard Clin Victor Hugo, Le Mans, France

[32] GINECO, Le Mans, France

[33] Univ Frauenklin Erlangen, Erlangen, Germany

[34] AGO, Erlangen, Germany

[35] Ctr CARIO HPCA, Plerin Sur Mer, France

[36] GINECO, Plerin Sur Mer, France

[37] Hochtaunuskliniken, Bad Homburg, Germany

[38] AGO, Bad Homburg, Germany

[39] ARCAGY Res, Paris, France

[40] GINECO, Paris, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

5550

引用

页数：1

共 39 条

[31] Efficacy of olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by lines of prior chemotherapy: Phase III SOLO2 trial (ENGOT Ov-21)
Penson, R.
Kaminsky-Forrett, M-C.
Ledermann, J.
Brown, C.
Plante, M.
Korach, J.
Huzarski, T.
Lista, A. Gomez de Liano
Pisano, C.
Friedlander, M.
Colombo, N.
Gropp-Meier, M.
Nakai, H.
Sonke, G. S.
Kim, J-W.
Vergote, I.
Allen, A.
Pujade-Lauraine, E.
ANNALS OF ONCOLOGY, 2017, 28
[32] Maintenance olaparib plus bevacizumab (bev) after platinum-based chemotherapy plus bev in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): Efficacy by timing of surgery and residual tumor status in the Phase III PAOLA-1 trial
Grimm, C.
Cropet, C.
Ray-Coquard, I.
GYNECOLOGIC ONCOLOGY, 2020, 159 : 19 - 19
[33] Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): RECIST and/or CA-125 objective response rate (ORR) in the phase III PAOLA-1 trial
Colombo, N.
Gantzer, J.
Ataseven, B.
Cropet, C.
Scambia, G.
Herrero, A.
Sevelda, P.
Kobayashi, H.
Vuylsteke, P.
Mirza, M. R.
Priou, F.
Buderath, P.
Pisano, C.
Lainez, N.
Guillemet, C.
Burges, A.
Sverdlin, R.
El-Balat, A.
Raban, N.
Ray-Coquard, I. L.
ANNALS OF ONCOLOGY, 2020, 31 : S614 - S614
[34] Maintenance olaparib plus bevacizumab (bev) after platinum-based chemotherapy plus bev in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): Efficacy by BRCA1 or BRCA2 mutation in the phase III PAOLA-1 trial.
Lorusso, Domenica
Lotz, Jean-Pierre
Harter, Philipp
Cropet, Claire
Perez, Maria Jesus Rubio
Schauer, Christian
Matsumoto, Takashi
Vergote, Ignace
Colombo, Nicoletta
Noettrup, Trine Jakobi
Bourgeois, Hugues Pierre
Schnelzer, Andreas
Pignata, Sandre
Garcia, Yolanda
Provansal, Magali
Hanker, Lars Christian
Berton, Dominique
Bauerschlag, Dirk
Joly, Florence
Ray-Coquard, Isabelle Laure
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[35] Time to second progression (PFS2) and second subsequent therapy (TSST) for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) treated with maintenance (mt) olaparib (ola): Phase III SOLO1 trial
Oaknin, A.
Moore, K.
Colombo, N.
Scambia, G.
Kim, B-G.
Friedlander, M.
Lisyanskaya, A.
Floquet, A.
Leary, A.
Sonke, G. S.
Gourley, C.
Banerjee, S.
Oza, A. M.
Gonzalez-Martin, A.
Aghajanian, C.
Bradley, W.
Lowe, E. S.
Bloomfield, R.
DiSilvestro, P.
ANNALS OF ONCOLOGY, 2019, 30 : 405 - 405
[36] Efficacy of maintenance olaparib for newly diagnosed, advanced ovarian cancer patients (pts) by BRCA1 or BRCA2 mutation in the phase III SOLO1 trial.
Friedlander, Michael
Moore, Kathleen N.
Colombo, Nicoletta
Scambia, Giovanni
Kim, Byoung-Gie
Oaknin, Ana
Lisyanskaya, Alla Sergeevna
Floquet, Anne
Leary, Alexandra
Sonke, Gabe S.
Gourley, Charlie
Banerjee, Susana N.
Oza, Amit M.
Gonzalez-Martin, Antonio
Aghajanian, Carol
Bradley, William Hampton
Lowe, Elizabeth S.
Bloomfield, Ralph
Disilvestro, Paul
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[37] Maintenance olaparib after platinum-based chemotherapy in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): Efficacy by surgical and tumor status in the Phase III SOLO1 trial.
Mathews, Cara Amanda
Moore, Kathleen N.
Colombo, Nicoletta
Scambia, Giovanni
Kim, Byoung-Gie
Oaknin, Ana
Friedlander, Michael
Lisyanskaya, Alla Sergeevna
Floquet, Anne
Leary, Alexandra
Sonke, Gabe S.
Gourley, Charlie
Banerjee, Susana N.
Oza, Amit M.
Gonzalez-Martin, Antonio
Aghajanian, Carol
Bradley, William Hampton
Lowe, Elizabeth S.
Bloomfield, Ralph
Disilvestro, Paul
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[38] MAINTENANCE OLAPARIB AFTER PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED ADVANCED OVARIAN CANCER AND A BRCA MUTATION: EFFICACY BY THE TIMING OF SURGERY AND RESIDUAL TUMOUR STATUS FOLLOWING UPFRONT OR INTERVAL CYTOREDUCTIVE SURGERY IN THE PHASE III SOLO1 TRIAL
Moore, K.
Colombo, N.
Scambia, G.
Kim, B-G
Oaknin, A.
Friedlander, M.
Lisyanskaya, A.
Floquet, A.
Leary, A.
Sonke, G. S.
Gourley, C.
Banerjee, S.
Oza, A.
Gonzalez-Martin, A.
Aghajanian, C.
Bradley, W.
Mathews, C.
Liu, J.
Lowe, E. S.
Bloomfield, R.
DiSilvestro, P.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A14 - A15
[39] Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): Results from the randomized, placebo (pbo)-controlled phase III DUO-O trial
Harter, Philipp
Trillsch, Fabian
Okamoto, Aikou
Reuss, Alexander
Kim, Jae-Weon
Rubio-Perez, Maria Jesus
Vardar, Mehmet Ali
Scambia, Giovanni
Tredan, Olivier
Nyvang, Gitte-Bettina
Colombo, Nicoletta
Chudecka-Glaz, Anita M.
Grimm, Christoph
Lheureux, Stephanie
Van Nieuwenhuysen, Els
Heitz, Florian
Wenham, Robert M.
Ushijima, Kimio
Day, Emily
Aghajanian, Carol
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17)

← 1 2 3 4 →